{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:54:44Z","timestamp":1792652084121,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01972-w","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T03:09:43Z","timestamp":1765854583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Beyond the DNA sequence: mapping the dynamic epigenetic landscape for risk stratification and therapeutic intervention in acute myeloid leukemia\u00a0"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Jiqian","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"1972_CR1","doi-asserted-by":"crossref","unstructured":"Schrezenmeier J, Huntly BJP. Epigenetic dysregulation in acute myeloid leukemia. Seminars in Hematology; 2025.","DOI":"10.1053\/j.seminhematol.2025.06.003"},{"key":"1972_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06387-x","author":"OS Aval","year":"2025","unstructured":"Aval OS, et al. Galectin-9: a double-edged sword in acute myeloid leukemia. Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-025-06387-x.","journal-title":"Ann Hematol"},{"key":"1972_CR3","doi-asserted-by":"publisher","unstructured":"Boscaro E, et al. Modern risk stratification of acute myeloid leukemia in 2023: integrating established and emerging prognostic factors. Cancers (Basel). 15(13) 3512 2023. https:\/\/doi.org\/10.3390\/cancers15133512.","DOI":"10.3390\/cancers15133512"},{"issue":"13","key":"1972_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/onc.2016.315","volume":"36","author":"CT Tsai","year":"2017","unstructured":"Tsai CT, So CWE. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene. 2017;36(13):1753\u20139.","journal-title":"Oncogene"},{"key":"1972_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/103175","volume":"2014","author":"E Conway O\u2019Brien","year":"2014","unstructured":"Conway O\u2019Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014;2014:p103175.","journal-title":"Adv Hematol"},{"issue":"5","key":"1972_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0324380","volume":"20","author":"J Li","year":"2025","unstructured":"Li J, Wang S. Integrative analysis of epigenetic subtypes in acute myeloid leukemia: a multi-center study combining machine learning for prognostic and therapeutic insights. PLoS One. 2025;20(5):e0324380.","journal-title":"PLoS One"},{"issue":"1","key":"1972_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M, et al. The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Exp Med. 2025;25(1):230.","journal-title":"Clin Exp Med"},{"key":"1972_CR8","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5287","author":"MA Issah","year":"2021","unstructured":"Issah MA, et al. Epigenetic modifications in acute myeloid leukemia: the emerging role of circular RNAs (Review). Int J Oncol. 2021. https:\/\/doi.org\/10.3892\/ijo.2021.5287.","journal-title":"Int J Oncol"},{"issue":"4","key":"1972_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/CM9.0000000000000624","volume":"133","author":"FY Wang","year":"2020","unstructured":"Wang FY, Gu ZY, Gao CJ. Emerging role of long non-coding RNAs in normal and malignant hematopoiesis. Chin Med J (Engl). 2020;133(4):462\u201373.","journal-title":"Chin Med J (Engl)"},{"key":"1972_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104916","volume":"215","author":"M Huang","year":"2025","unstructured":"Huang M, et al. Epigenetic mechanisms and next-gen editing platforms in hematology: from molecular basis to therapeutic frontiers. Crit Rev Oncol Hematol. 2025;215:104916.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1972_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03763-5","volume":"25","author":"M Farajzadeh","year":"2025","unstructured":"Farajzadeh M, et al. Long noncoding RNAs in acute myeloid leukemia: biomarkers, prognostic indicators, and treatment potential. Cancer Cell Int. 2025;25(1):131.","journal-title":"Cancer Cell Int"},{"key":"1972_CR12","doi-asserted-by":"crossref","unstructured":"Sharma S. Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: new prospects & challenges. Volume 9. Non-coding RNA Research; 2024. pp. 1203\u201321. 4.","DOI":"10.1016\/j.ncrna.2024.05.009"},{"issue":"8","key":"1972_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/2159-8290.CD-16-1032","volume":"7","author":"JL Glass","year":"2017","unstructured":"Glass JL, et al. Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers. Cancer Discov. 2017;7(8):868\u201383.","journal-title":"Cancer Discov"},{"issue":"7","key":"1972_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2011.39.2092","volume":"30","author":"G Marcucci","year":"2012","unstructured":"Marcucci G, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742\u201350.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1972_CR15","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1182\/blood-2008-07-170589","volume":"113","author":"R Garzon","year":"2009","unstructured":"Garzon R, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411\u20138.","journal-title":"Blood"},{"issue":"2","key":"1972_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1600-0609.2011.01716.x","volume":"88","author":"J Markov\u00e1","year":"2012","unstructured":"Markov\u00e1 J, et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol. 2012;88(2):128\u201335.","journal-title":"Eur J Haematol"},{"issue":"1","key":"1972_CR17","first-page":"275","volume":"104","author":"S Iyama","year":"2025","unstructured":"Iyama S, et al. Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study. Ann Hematol. 2025;104(1):275\u201384.","journal-title":"Ann Hematol"},{"issue":"1","key":"1972_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01580-z","volume":"15","author":"M Schmutz","year":"2023","unstructured":"Schmutz M, et al. Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen. Clin Epigenetics. 2023;15(1):171.","journal-title":"Clin Epigenetics"},{"issue":"6","key":"1972_CR19","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s10238-022-00980-4","volume":"23","author":"J Jian","year":"2023","unstructured":"Jian J, et al. DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features. Clin Exp Med. 2023;23(6):2639\u201349.","journal-title":"Clin Exp Med"},{"issue":"23","key":"1972_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.21037\/atm.2019.11.122","volume":"7","author":"L Hu","year":"2019","unstructured":"Hu L, et al. DNA methylation-based prognostic biomarkers of acute myeloid leukemia patients. Ann Transl Med. 2019;7(23):737.","journal-title":"Ann Transl Med"},{"key":"1972_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14744\/ejmo.2023.35138","volume":"2023","author":"A Zahran","year":"2023","unstructured":"Zahran A, et al. Disturbed expression of memory T-Cell subsets could alter the outcomes in adult acute myeloid leukemia. Eurasian J Med Oncol. 2023;2023:362\u201370.","journal-title":"Eurasian J Med Oncol"},{"issue":"1","key":"1972_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00842-4","volume":"12","author":"S Rauschert","year":"2020","unstructured":"Rauschert S, et al. Machine learning and clinical epigenetics: a review of challenges for diagnosis and classification. Clin Epigenetics. 2020;12(1):51.","journal-title":"Clin Epigenetics"},{"key":"1972_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.143668","volume":"311","author":"X Feng","year":"2025","unstructured":"Feng X, et al. Autofe-pointer: auto-weighted feature extractor based on pointer network for DNA methylation prediction. Int J Biol Macromol. 2025;311:143668.","journal-title":"Int J Biol Macromol"},{"key":"1972_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1455572","volume":"12","author":"P Yadav","year":"2024","unstructured":"Yadav P, Jain R, Yadav RK. Emerging roles of cancer-associated histone mutations in genomic instabilities. Front Cell Dev Biol. 2024;12:1455572.","journal-title":"Front Cell Dev Biol"},{"key":"1972_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.exphem.2020.09.189","volume":"92","author":"LD Boila","year":"2020","unstructured":"Boila LD, Sengupta A. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy. Exp Hematol. 2020;92:19\u201331.","journal-title":"Exp Hematol"},{"issue":"1","key":"1972_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00366-0","volume":"10","author":"A Katebi","year":"2024","unstructured":"Katebi A, et al. Data-driven modeling of core gene regulatory network underlying leukemogenesis in IDH mutant AML. NPJ Syst Biol Appl. 2024;10(1):38.","journal-title":"NPJ Syst Biol Appl"},{"key":"1972_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2025.104986","volume":"414","author":"I Ahmad","year":"2025","unstructured":"Ahmad I, et al. Mesenchymal stem cell-derived exosomes (MSC-exosomes) in hematology: from mechanisms to clinical breakthroughs. Cell Immunol. 2025;414:104986.","journal-title":"Cell Immunol"},{"issue":"6","key":"1972_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02742-0","volume":"42","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders. Med Oncol. 2025;42(6):199.","journal-title":"Med Oncol"},{"issue":"20 Pt A","key":"1972_CR29","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.febslet.2015.08.044","volume":"589","author":"J Dekker","year":"2015","unstructured":"Dekker J. E Heard 2015 Structural and functional diversity of topologically associating domains. FEBS Lett 589 20 Pt A 2877\u201384.","journal-title":"FEBS Lett"},{"issue":"4","key":"1972_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkae1267","volume":"53","author":"D Dang","year":"2024","unstructured":"Dang D, et al. Uncovering topologically associating domains from three-dimensional genome maps with TADGATE. Nucleic Acids Res. 53(4), 1-19 2024. https:\/\/doi.org\/10.1093\/nar\/gkae1267.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1972_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-04819-w","volume":"6","author":"S Rajderkar","year":"2023","unstructured":"Rajderkar S, et al. Topologically associating domain boundaries are required for normal genome function. Commun Biol. 2023;6(1):435.","journal-title":"Commun Biol"},{"issue":"11","key":"1972_CR32","doi-asserted-by":"publisher","first-page":"R611","DOI":"10.1530\/ERC-19-0348","volume":"26","author":"MJ Campbell","year":"2019","unstructured":"Campbell MJ. Tales from topographic oceans: topologically associated domains and cancer. Endocr Relat Cancer. 2019;26(11):R611\u201326.","journal-title":"Endocr Relat Cancer"},{"issue":"7935","key":"1972_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-022-05365-x","volume":"611","author":"J Xu","year":"2022","unstructured":"Xu J, et al. Subtype-specific 3D genome alteration in acute myeloid leukaemia. Nature. 2022;611(7935):387\u201398.","journal-title":"Nature"},{"issue":"1","key":"1972_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01271-x","volume":"15","author":"S Deng","year":"2022","unstructured":"Deng S, Feng Y, Pauklin S. 3D chromatin architecture and transcription regulation in cancer. J Hematol Oncol. 2022;15(1):49.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1972_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10705-z","volume":"10","author":"M Boileau","year":"2019","unstructured":"Boileau M, et al. Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. Nat Commun. 2019;10(1):2891.","journal-title":"Nat Commun"},{"issue":"9","key":"1972_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2016.1272680","volume":"58","author":"Y Guo","year":"2017","unstructured":"Guo Y, et al. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. Leuk Lymphoma. 2017;58(9):1\u201315.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1972_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03772-4","volume":"25","author":"S Liu","year":"2025","unstructured":"Liu S, et al. The emerging functions and clinical implications of circRNAs in acute myeloid leukaemia. Cancer Cell Int. 2025;25(1):167.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1972_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01446-z","volume":"20","author":"V Singh","year":"2021","unstructured":"Singh V, et al. Circular RNAs in acute myeloid leukemia. Mol Cancer. 2021;20(1):149.","journal-title":"Mol Cancer"},{"issue":"1","key":"1972_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05562-4","volume":"22","author":"J Zhang","year":"2024","unstructured":"Zhang J, et al. CircRNA as an Achilles heel of cancer: characterization, biomarker and therapeutic modalities. J Transl Med. 2024;22(1):752.","journal-title":"J Transl Med"},{"issue":"5","key":"1972_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051554","volume":"15","author":"E Gharib","year":"2023","unstructured":"Gharib E, Nasrabadi PN, Robichaud GA. Circular RNA expression signatures provide promising diagnostic and therapeutic biomarkers for chronic lymphocytic leukemia. Cancers (Basel). 2023;15(5):1554.","journal-title":"Cancers (Basel)"},{"key":"1972_CR41","doi-asserted-by":"publisher","DOI":"10.4103\/jrms.jrms_287_24","volume":"30","author":"AH Aghayan","year":"2025","unstructured":"Aghayan AH, et al. Diagnostic value of circular RNAs as promising hematological biomarkers in acute myeloid leukemia: a systematic review and meta-analysis. J Res Med Sci. 2025;30:31.","journal-title":"J Res Med Sci"},{"issue":"6","key":"1972_CR42","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s00018-020-03720-7","volume":"78","author":"S Krishna","year":"2021","unstructured":"Krishna S, et al. tRNA-derived fragments (tRFs): establishing their turf in post-transcriptional gene regulation. Cell Mol Life Sci. 2021;78(6):2607\u201319.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1972_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02731-7","volume":"19","author":"Q Xiao","year":"2021","unstructured":"Xiao Q, et al. tRFTars: predicting the targets of tRNA-derived fragments. J Transl Med. 2021;19(1):88.","journal-title":"J Transl Med"},{"issue":"4","key":"1972_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115485","volume":"44","author":"K Kirio","year":"2025","unstructured":"Kirio K, et al. Circular RNAs exhibit exceptional stability in the aging brain and serve as reliable age and experience indicators. Cell Rep. 2025;44(4):115485.","journal-title":"Cell Rep"},{"issue":"6","key":"1972_CR45","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1109\/TCBB.2022.3143770","volume":"19","author":"W Li","year":"2022","unstructured":"Li W, et al. Inferring latent microRNA-disease associations on a gene-mediated tripartite heterogeneous multiplexing network. IEEE ACM Trans Comput Biol Bioinform. 2022;19(6):3190\u2013201.","journal-title":"IEEE ACM Trans Comput Biol Bioinform"},{"issue":"1","key":"1972_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06659-0","volume":"23","author":"XP Li","year":"2025","unstructured":"Li XP, et al. A multi-omic single-cell landscape reveals transcription and epigenetic regulatory features of t(8;21) AML. J Transl Med. 2025;23(1):816.","journal-title":"J Transl Med"},{"issue":"1","key":"1972_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-05120-6","volume":"6","author":"H Fan","year":"2023","unstructured":"Fan H, et al. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance. Commun Biol. 2023;6(1):765.","journal-title":"Commun Biol"},{"key":"1972_CR48","doi-asserted-by":"publisher","unstructured":"Nuno K, et al. Convergent epigenetic evolution drives relapse in acute myeloid leukemia. Elife. 22(13) 2024. https:\/\/doi.org\/10.7554\/eLife.93019.","DOI":"10.7554\/eLife.93019"},{"issue":"1","key":"1972_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02340-6","volume":"10","author":"C Galassi","year":"2025","unstructured":"Galassi C, et al. Epigenetic regulation of cancer stemness. Signal Transduct Target Ther. 2025;10(1):243.","journal-title":"Signal Transduct Target Ther"},{"key":"1972_CR50","doi-asserted-by":"crossref","unstructured":"Whittle J, et al. Single-Cell atlas of AML reveals Age-Related gene regulatory networks in t(8;21) AML. eLife Sciences Publications, Ltd.; 2025.","DOI":"10.7554\/eLife.104978.2"},{"key":"1972_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","volume":"83","author":"L Guo","year":"2022","unstructured":"Guo L, et al. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Semin Cancer Biol. 2022;83:487\u2013502.","journal-title":"Semin Cancer Biol"},{"key":"1972_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2024","unstructured":"Sadida HQ, et al. Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl Oncol. 2024;39:101821.","journal-title":"Transl Oncol"},{"key":"1972_CR53","doi-asserted-by":"publisher","first-page":"854797","DOI":"10.3389\/fcell.2022.854797","volume":"10","author":"W Wagner","year":"2022","unstructured":"Wagner W. How to translate DNA methylation biomarkers into clinical practice. Front Cell Dev Biol. 2022;10:854797.","journal-title":"Front Cell Dev Biol"},{"key":"1972_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.amolm.2023.100023","volume":"2","author":"A Quattrocchi","year":"2023","unstructured":"Quattrocchi A, et al. Biomarkers in acute myeloid leukemia: from state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target. Aspects Mol Med. 2023;2:100023.","journal-title":"Aspects Mol Med"},{"issue":"6","key":"1972_CR55","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1200\/JCO.2013.50.6337","volume":"32","author":"G Marcucci","year":"2014","unstructured":"Marcucci G, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014;32(6):548\u201356.","journal-title":"J Clin Oncol"},{"key":"1972_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1275251","volume":"14","author":"K Bhatia","year":"2024","unstructured":"Bhatia K, et al. Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches. Front Oncol. 2024;14:1275251.","journal-title":"Front Oncol"},{"issue":"2","key":"1972_CR57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11899-021-00621-9","volume":"16","author":"NR Grieselhuber","year":"2021","unstructured":"Grieselhuber NR, Mims AS. Novel targeted therapeutics in acute myeloid leukemia: an embarrassment of riches. Curr Hematol Malig Rep. 2021;16(2):192\u2013206.","journal-title":"Curr Hematol Malig Rep"},{"key":"1972_CR58","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3923\/ijp.2023.632.641","volume":"19","author":"Q Su","year":"2023","unstructured":"Su Q, et al. Dihydroartemisinin increases the sensitivity of acute myeloid leukemia cells to cytarabine via the Nrf2\/HO-1 anti-oxidant signaling pathway. Int J Pharmacol. 2023;19:632\u201341.","journal-title":"Int J Pharmacol"},{"issue":"1","key":"1972_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01632-8","volume":"17","author":"KVG Nadiminti","year":"2024","unstructured":"Nadiminti KVG, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol Oncol. 2024;17(1):113.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1972_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, et al. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"key":"1972_CR61","first-page":"12","volume":"14","author":"A Berberabe","year":"2025","unstructured":"Berberabe A. Expanding Menin inhibitors in acute myeloid leukemia. Target Ther Oncol. 2025;14:12.","journal-title":"Target Ther Oncol"},{"key":"1972_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.06.002","author":"L Boussi","year":"2025","unstructured":"Boussi L, Cai SF, Stein EM. Advances in menin inhibition in acute myeloid leukemia. Trends Cancer. 2025. https:\/\/doi.org\/10.1016\/j.trecan.2025.06.002.","journal-title":"Trends Cancer"},{"issue":"6","key":"1972_CR63","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","volume":"145","author":"G Huls","year":"2025","unstructured":"Huls G, Woolthuis CM, Schuringa JJ. Menin inhibitors in the treatment of acute myeloid leukemia. Blood. 2025;145(6):561\u20136.","journal-title":"Blood"},{"key":"1972_CR64","doi-asserted-by":"crossref","unstructured":"Kivrak M, Nalkiran I, Sevim H, Nalkiran. Exploring the therapeutic potential of the DOT1L inhibitor EPZ004777 using bioinformatics and molecular Docking approaches in acute myeloid leukemia. Curr Issues Mol Biol, 2025. 47(3), pg 1-23.","DOI":"10.3390\/cimb47030173"},{"issue":"4","key":"1972_CR65","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/14728214.2019.1694001","volume":"24","author":"MR Pandey","year":"2019","unstructured":"Pandey MR, Wang ES. What potential is there for LSD1 inhibitors to reach approval for AML? Expert Opin Emerg Drugs. 2019;24(4):205\u201312.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1972_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105335","volume":"164","author":"S Zhang","year":"2021","unstructured":"Zhang S, et al. Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacol Res. 2021;164:105335.","journal-title":"Pharmacol Res"},{"key":"1972_CR67","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2147\/JIR.S499403","volume":"18","author":"S Zhang","year":"2025","unstructured":"Zhang S, et al. The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy. J Inflamm Res. 2025;18:4335\u201357.","journal-title":"J Inflamm Res"},{"issue":"1","key":"1972_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01858-x","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H. Integrating multi-omics approaches in acute myeloid leukemia (AML): advancements and clinical implications. Clin Exp Med. 2025;25(1):311.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1972_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010071","volume":"26","author":"F Ahmed","year":"2025","unstructured":"Ahmed F, Zhong J. Advances in DNA\/RNA sequencing and their applications in acute myeloid leukemia (AML). Int J Mol Sci. 2025;26(1):71.","journal-title":"Int J Mol Sci"},{"key":"1972_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00817","volume":"8","author":"B He","year":"2020","unstructured":"He B, et al. Assessing the impact of data preprocessing on analyzing next generation sequencing data. Front Bioeng Biotechnol. 2020;8:817.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"1972_CR71","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.seminhematol.2014.08.003","volume":"51","author":"ER Mardis","year":"2014","unstructured":"Mardis ER. Sequencing the AML genome, transcriptome, and epigenome. Semin Hematol. 2014;51(4):250\u20138.","journal-title":"Semin Hematol"},{"issue":"3","key":"1972_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2040620715577614","volume":"6","author":"P Gallipoli","year":"2015","unstructured":"Gallipoli P, Giotopoulos G, Huntly BJ. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Ther Adv Hematol. 2015;6(3):103\u201319.","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"1972_CR73","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"issue":"1","key":"1972_CR74","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin Exp Med. 2025;25(1):215.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1972_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01795-9","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. Clin Exp Med. 2025;25(1):240.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1972_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep. 2025;52(1):464.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1972_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"1","key":"1972_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58921-0","volume":"16","author":"G Zhang","year":"2025","unstructured":"Zhang G, et al. TRAPT: a multi-stage fused deep learning framework for predicting transcriptional regulators based on large-scale epigenomic data. Nat Commun. 2025;16(1):3611.","journal-title":"Nat Commun"},{"issue":"1","key":"1972_CR79","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6782046","volume":"2020","author":"B He","year":"2020","unstructured":"He B, et al. Gene coexpression network and module analysis across 52 human tissues. Biomed Res Int. 2020;2020(1):6782046.","journal-title":"Biomed Res Int"},{"issue":"6","key":"1972_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06244-4","volume":"151","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML. J Cancer Res Clin Oncol. 2025;151(6):193.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01972-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T04:38:25Z","timestamp":1765859905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01972-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1972"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01972-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}